Director of Research – Chennai, Tamil Nadu (IN)
Applications are invited for the post of Director of Research at Cancer Institute (WIA), Chennai, India.
Related Articles
The ENTIRE healthcare system is broken, not just health insurance companies
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,…
Adobe Acrobat – The-Impact-of-New-Products-on-Ethical-Beliefs.pdf
View this file, and add comments too.
Novel approaches in myelofibrosis
Myelofibrosis (MF) is a clonal myeloid neoplasm characterized by bone marrow fibrosis, splenomegaly, and disease-associated symptoms, as well as increased mortality, due to thrombosis, severe…
What have we learned about TP53-mutated acute myeloid leukemia?
Blood Cancer Journal – What have we learned about TP53-mutated acute myeloid leukemia?
City of Hope Buys 52 Acres in Orange County for $89M
The cancer treatment network paid $108M in 2020 for 11 acres and a 190K-SF building there to build its Lennar Foundation Cancer Center.
Seminal Trials: IPASS for EGFR NSCLC | IASLC
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator,…
Spatial transcriptomic clocks reveal cell proximity effects in brain ageing
Nature – A spatially resolved single-cell transcriptomics map of the mouse brain at different ages reveals signatures of ageing, rejuvenation and disease, including ageing effects…
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer | JCO Oncology Practice
PURPOSEFinancial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with…
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma | Research To Practice
Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET) Program Schedule — Pacific Time 2:45…
Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial
Stereotactic body radiotherapy (SBRT) is increasingly used to treat early-stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Excellent rates of local control (87 %-95 %)…
